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Over the last 20 years, breast cancer has been something of a
success story in the United Kingdom, with a 20% decrease in
mortality despite a steadily increasing incidence. This is welcome
news, but the underlying explanation is the topic of much debate.
The widespread use of adjuvant medical therapies, the introduc-
tion of a national mammographic screening programme, and
increased breast awareness all have their advocates. It is likely that
all these factors are involved to a varying extent.
THE UNCERTAIN ROLE OF SCREENING
The NHS breast cancer screening programme was introduced in
1988 after mortality from breast cancer had already begun to
decrease and was based on the results from eight randomized trials
showing that screening reduced mortality by 20–30% especially
for women between 50 and 69 years of age. Since then, the
methodology of these trials and the magnitude of survival benefit
have been the subject of continuous debate (Olsen and Gotzsche,
2001; Baum, 2004). The absolute survival benefit from screening is
difficult to quantify in the setting of concomitant advances in the
management of breast cancer. Some critics argue that the harms of
screening mammography, for example, false positives with
resulting unnecessary procedures and increased anxiety, may
actually outweigh the benefits (Gotzsche, 2004). What is certainly
clear is that screening has led to a dramatic increase in the
incidence of ductal carcinoma in situ (DCIS). DCIS is a non-
invasive form of breast cancer, usually detected as asymptomatic
microcalcifications on mammography, which may or may not
progress to invasive cancer. Before the NHS screening programme,
DCIS had been a rare diagnosis, but now it accounts for
approximately 20% of screen-diagnosed breast cancers (Moss
et al, 1995). When appropriately treated, this non-invasive cancer
has an excellent prognosis (10-year RR of death from breast
cancer, 2%; Ernster et al, 2000) and therefore has clearly
contributed to the rising incidence of breast cancer while
improving survival rates, but the impact on mortality of this
dramatic increase in diagnosis remains uncertain. Reviews of
autopsy series have revealed that DCIS is an incidental finding in
9% of women dying of non-breast cancer-related causes (Welch
and Black, 1997), suggesting that screen-detected DCIS may lead to
overdiagnosis in some women. Likewise, retrospective studies have
demonstrated that only 15–50% of untreated DCIS will progress to
invasive disease (Erbas et al, 2006). The problem lies in identifying
which ones will.
BREAST AWARENESS
Despite the high media profile for breast self-examination (BSE),
an approach of systematic BSE has not been shown to improve
survival and may actually cause anxiety and unnecessary biopsies
(Kosters and Gotzsche, 2003). Breast awareness, however, is still
promoted and involves encouraging women to recognise and
report without delay any unusual breast changes (McCready et al,
2005). Improved public education about breast cancer combined
with increased screening has led to a stage shift, with more women
presenting with early disease.
ADVANCES IN THE TREATMENT OF EARLY
BREAST CANCER
Loco-regional treatment
Surgery has always been central to the management of early
breast cancer. Over the last few decades, however, it has
become clear that access to surgical specialists is an important
predictor of long-term outcome. Women with early breast
cancer treated by specialist surgeons have lower local recurrence
rates and an improved survival compared with those treated
by non-specialists (Kingsmore et al, 2004). This benefit is in
part attributable to higher rates of adequate local treatment
of the breast and/or axilla. Increased access to specialist
surgeons and the establishment of national guidelines for the
surgical management of breast cancer (Quality assurance
guidelines for surgeons in breast cancer screening, in
Publication No. 20, N. BSP, Editor, 1992) have therefore
contributed to survival improvements. Similarly, standardisation
of pathology reporting and the use of specialized breast
pathologists have been important factors in improving the
quality of care delivered to women with breast cancer (Program,
UNS, Pathology Reporting in Breast Cancer Screening,i n
2nd edition, NPN 3, Editor, 1997: Sheffield UK). Finally,
radiotherapy after breast-conserving surgery and after
mastectomy in selected high-risk patients has been shown to
improve not only loco-regional control, but also long-term survival
(5% reduction in 15-year breast cancer mortality) (Clarke et al,
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The last two decades have seen tremendous advances in the adjuvant
treatment of early breast cancer. In 1985, the Nolvadex Adjuvant
Trial Organisation study was the first randomised trial to show an
overall survival advantage in patients receiving adjuvant treatment
with the selective oestrogen receptor modulator, tamoxifen (NATO,
1985). Since then, a series of reviews have confirmed that 5 years of
post-operative tamoxifen for pre- and post-menopausal women with
ERþ breast cancer reduces mortality by over 25% at up to 15 years
of follow-up (EBCTCG, 1998a; EBCTCG, 2005).
Adjuvant chemotherapy trial data also began to emerge in the
early 1980s, again suggesting a survival benefit particularly for
young women (EBCTCG, 1988). Subsequent overview results
confirmed a proportional mortality reduction of 27 and 11%
among women below and above the age of 50, respectively,
regardless of nodal status (EBCTCG, 1998b). Efforts have been
made to determine the optimal cytotoxic regimen. The standard
post-operative treatment in most early trials was CMF polyche-
motherapy (cyclophosphamide, methotrexate, and 5-fluorouracil),
but recent evidence suggests that there is a small but highly
significant further survival benefit with anthracycline-based regi-
mens (RR¼0.89; 2 Po0.00001) (EBCTCG, 2005), and these have
become widely accepted as standard adjuvant chemotherapy.
The most recent overview suggests that breast cancer mortality
may actually be halved by a combination of endocrine therapy and
chemotherapy after surgery in women with hormone receptor-
positive disease (EBCTCG, 2005). As these account for more than
two-thirds of newly diagnosed breast cancer patients, it is likely
that the increasing use of adjuvant therapy has had an important
function in breast cancer survival improvement.
ADVANCES IN THE TREATMENT OF METASTATIC
BREAST CANCER
A number of new cytotoxic, endocrine and targeted agents have
been licensed for breast cancer over the last 15 years and have
greatly increased treatment options for advanced disease (Smith,
2002). Although the impact on overall survival trends is likely to be
modest, the incorporation of these new therapies into clinical
practice has been shown to significantly prolong survival from
metastatic breast cancer (OS from metastatic breast cancer: 438
days vs 667 days for women treated in 1991–1992 vs 1999–2001;
Chia et al, 2007). By increasing the number of effective anti-cancer
agents, and improving palliative strategies by offering radio-
therapy for symptomatic bone and brain lesions, or surgical
treatment of spinal and brain metastases, tremendous gains have
been achieved in improving both the quality of life and survival of
women with advanced breast cancer.
THE DEPRIVATION GAP
Quinn et al (2008) draw attention to the observation that although
the incidence of breast cancer has risen more rapidly among
affluent women, the deprivation gap (difference in survival from
breast cancer for women from affluent vs deprived background)
has not changed. This may in part be due to the fact that women
from a higher socioeconomic background are more likely to
undergo mammography and therefore be diagnosed with a small
screen-detected breast cancer (Taylor and Cheng, 2003). However,
as Quinn et al (2008) point out, if screening were the sole reason
for the increased incidence, this should have led to a stage shift in
the affluent group and a widening in the deprivation gap. Women
of higher socioeconomic status are also at increased risk of
developing invasive breast cancer due to differing reproductive
behaviours of aetiological significance, for example, late age at first
birth, low parity, and low breastfeeding rates (Kelsey et al, 1981).
The incidence trend may therefore also reflect changes in
reproductive habits and possibly in the use of hormone replace-
ment therapy among affluent women.
OPTIMISM FOR THE FUTURE
On the premise that adjuvant medical therapies are a major factor
in survival improvement, it is likely that this trend will continue
with the emergence of new and more effective therapies.
Several trials have shown that adjuvant aromatase inhibitors
achieve superior disease-free survival to tamoxifen in post-
menopausal women, and it seems likely that this will translate
into a further small survival improvement (Lin and Winer, 2008).
Specifically, the MA-17 trial has demonstrated a significant
improvement in disease-free survival for letrozole vs placebo after
5 years of tamoxifen and a significant overall survival benefit in
women with node-positive disease (HR¼0.61, P¼0.04) (Goss
et al, 2005), raising the concept of long-term maintenance
endocrine therapy for 10 years or more in selected patients.
Adjuvant trastuzumab (Herceptin) has recently shown an
impressive 50% reduction in the risk of early recurrence and a
30% reduction in mortality relative to placebo in women with
HER2-positive breast cancer (Romond et al, 2005; Dinh et al,
2007). Although this involves only 15% of breast cancer patients,
these represent a high-risk group, and the proof of principle gives
optimism for further targeted therapies now in development.
Perhaps as important as the development of novel therapies is
the development of tools to identify women with good prognosis
who could benefit from more conservative treatment. Some of the
new techniques include sentinel node biopsy to identify patients
who may be spared axillary dissection and gene expression profiles
to identify women at low risk of recurrence who may be spared
adjuvant chemotherapy.
Finally, the changes in cancer treatment provision such as the
increasing use of multidisciplinary teams, one-stop triple assess-
ment clinics for symptomatic breast complaints and breast cancer
nurse specialists will undoubtedly continue to optimise the quality
of care offered to women with breast cancer.
CONCLUSION
Improvements in breast cancer diagnosis and treatment in the UK
have had an important impact on survival, and it is reasonable to
expect that the outlook will continue to improve over the next
decade. Governmental guidelines implemented in the late 1990s
designed to reduce delays and improve multidisciplinary organisa-
tion and the continuing development of more effective medical
therapies are both making important contributions. The political
challenge is to ensure equal access to best care for women
from deprived backgrounds. The medical challenge is to select
through molecular profiling which patients are most likely
to benefit from the ever-expanding medical treatment options
and which can be spared unnecessary toxicities. The good news is
likely to continue.
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